Advertisement
UK markets closed

  • FTSE 100

    8,383.94
    +29.89 (+0.36%)
     

  • FTSE 250

    20,542.56
    +50.57 (+0.25%)
     

  • AIM

    783.20
    +3.37 (+0.43%)
     

  • GBP/EUR

    1.1612
    -0.0010 (-0.09%)
     

  • GBP/USD

    1.2515
    +0.0017 (+0.14%)
     

  • Bitcoin GBP

    49,598.73
    -97.18 (-0.20%)
     

  • CMC Crypto 200

    1,331.34
    +31.24 (+2.40%)
     

  • S&P 500

    5,206.62
    +18.95 (+0.37%)
     

  • DOW

    39,248.03
    +191.64 (+0.49%)
     

  • CRUDE OIL

    79.23
    +0.24 (+0.30%)
     

  • GOLD FUTURES

    2,341.90
    +19.60 (+0.84%)
     

  • NIKKEI 225

    38,073.98
    -128.39 (-0.34%)
     

  • HANG SENG

    18,537.81
    +223.95 (+1.22%)
     

  • DAX

    18,692.47
    +194.09 (+1.05%)
     

  • CAC 40

    8,186.76
    +55.35 (+0.68%)
     
Money:

Best UK mortgage deals of the week

As Bank of England holds interest rates, here's what high street banks are offering home buyers

Vectura Group appoints AstraZeneca executive as CEO

Reuters - UK Focus

June 24 (Reuters) - Respiratory drugs specialist Vectura Group Plc appointed AstraZeneca (NYSE: AZN - news) executive James Ward-Lilley as chief executive officer effective Oct. 1.

Ward-Lilley replaces Chris Blackwell, who will leave the company at the end of this month.

Ward-Lilley is currently vice president at AstraZeneca and responsible for respiratory, inflammation and autoimmunity strategy, which has included the recent acquisitions of Almirall's respiratory business and Pearl Therapeutics, Vectura said in a statement.

Trevor Phillips will continue as interim CEO from the end of June until Ward-Lilley joins the company, it added. (Reporting by Roshni Menon in Bengaluru; Editing by Anupama Dwivedi)